We are evolving targeted protein degradation to transform the landscape of drug discovery by utilizing the cell’s normal protein regulation systems to remove disease causing proteins that cannot be targeted by traditional approaches. The NExMods™ Platform (NEosubstrate Expression Modulators) represents a novel approach to “molecular glues” capable of delivering impactful medicines to patients across diverse therapeutic areas: oncology, immuno-oncology, fibrosis, inflammation, and neurodegeneration.  Through our novel "function-first" approach, our goal is to expand the scope of degradable targets that cause human disease.

Our lead oncology monotherapy compound, FFT-012, degrades an undruggable transcription factor at the end of the Wnt pathway which provides multiple applications in solid tumors.  In addition to the Wnt and additional portfolio programs, we are engaging our oncology assets towards combinations with antibodies to provide novel Degrader Antibody Conjugates (DACs).  By replacing the cytotoxic payloads of an Antibody Drug Conjugate (ADC), f5 Therapeutics is attempting to widen the therapeutic index of this modality.

Biotechnology

Life Sciences

Pharmaceutical

f5 Therapeutics Incorporated

f5 Therapeutics Incorporated's headquarters in San Diego, United States

f5 Therapeutics Incorporated

Org chart

Teams

Offices

Similar companies